Background: Primary cardiac tumors are exceptionally rare, with cardiac myxomas being the most common benign type, typically originating in the left atrium. Despite their benign histopathological nature, these tumors can lead to serious complications, including intracardiac obstruction, embolic events, and even sudden cardiac death. The coexistence of a Left Atrial (LA) myxoma and Coronary Artery Disease (CAD) is an unusual clinical finding. This report highlights the importance of recognizing cardiac myxoma as a potential contributor to high-risk acute coronary syndrome and hemodynamic instability. Case Illustration: A 57-year-old man presented with recurrent chest pain and shortness of breath, consistent with very high-risk Non–ST Elevation Myocardial Infarction (NSTEMI) and cardiogenic shock. Transthoracic Echocardiography (TTE) revealed a large LA mass causing functional mitral valve obstruction, highly suggestive of a myxoma. Further evaluation with transesophageal echocardiography confirmed a giant, highly mobile mass intermittently occluding the mitral inflow. Coronary angiography revealed significant Two-Vessel Coronary Artery Disease (CAD2VD), including chronic total occlusion of the Left Circumflex Artery (LCx). The patient subsequently underwent urgent combined surgical excision of the tumor and Coronary Artery Bypass Grafting (CABG). Histopathological examination confirmed the diagnosis of cardiac myxoma. The postoperative course was uneventful, with marked clinical improvement, complete resolution of symptoms, and preserved ventricular function on follow-up echocardiography. Conclusions: This case of very high-risk NSTEMI with cardiogenic shock was further complicated by a large LA myxoma causing dynamic mitral obstruction and diastolic inflow collapse. Early recognition using multimodal imaging and prompt surgical management are essential to prevent catastrophic hemodynamic deterioration and improve patient outcomes.
11 July 2026 in Medcomm – Biomaterials and Applications
Stromal cell‐derived factor‐1α (SDF‐1α) is a potent stem cell recruitment chemokine that can promote angiogenesis, particularly when delivered via gene‐activated scaffolds (GAS). This systematic review and meta‐analysis synthesized in vitro evidence on the angiogenic potential of SDF‐1α GAS. Four databases were utilized to search for eligible studies, comprising investigations that examined the in vitro effects of SDF‐1α GAS on angiogenesis‐related outcomes compared with gene‐free scaffolds. Data on gene expression, protein levels, and endothelial formation were extracted. Meta‐analyses were conducted using random or fixed‐effect models, expressed as standardized mean difference (SMD) or mean difference (MD) with 95% confidence intervals (CI). Risk of bias was assessed using the Quality Assessment Tool for In Vitro Studies (QUIN) tool. Eight studies were included. Pooled analysis demonstrated SDF‐1α GAS efficacy to significantly increase SDF‐1α gene expression (SMD = 1.20; 95% CI = 0.13–2.27; p = .03), fold‐change of the gene (MD = 12.48; 95% CI = 10.33–14.64; p < .0001), and protein production (MD = 0.29 ng/mL; 95% CI = 0.14–0.43 ng/mL; p = .0001). Most studies showed a moderate risk of bias. Based on in vitro studies, SDF‐1α GAS activity is associated with significant elevation of SDF‐1α gene expression and protein quantity, although it did not exhibit significant enhancement of VEGF expression or functional endothelial morphogenesis under the studied conditions.